REFERENCES
1. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial
fibrillation and risks of cardiovascular disease, renal disease, and
death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
2. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG,
Lakkireddy D, Olshansky B. Arrhythmia-Induced Cardiomyopathies:
Mechanisms, Recognition, and Management. J Am Coll Cardiol.2015;66(15):1714-1728.
3. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses
L. A meta-analysis of the prognostic significance of atrial fibrillation
in chronic heart failure. Eur J Heart Fail. 2009;11(7):676-683.
4. Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone
for Treatment of Persistent Atrial Fibrillation in Patients With
Congestive Heart Failure and an Implanted Device: Results From the AATAC
Multicenter Randomized Trial. Circulation.2016;133(17):1637-1644.
5. Packer DL, Piccini JP, Monahan KH, et al. Ablation Versus Drug
Therapy for Atrial Fibrillation in Heart Failure: Results from the
CABANA Trial. Circulation. 2021.
6. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for
Atrial Fibrillation with Heart Failure. N Engl J Med.2018;378(5):417-427.
7. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess
catheter ablation versus rate control in the management of persistent
atrial fibrillation in heart failure. J Am Coll Cardiol.2013;61(18):1894-1903.
8. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial
of catheter ablation versus medical treatment of atrial fibrillation in
heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol.2014;7(1):31-38.
9. Kuck KH, Merkely B, Zahn R, et al. Catheter Ablation Versus Best
Medical Therapy in Patients With Persistent Atrial Fibrillation and
Congestive Heart Failure: The Randomized AMICA Trial. Circ
Arrhythm Electrophysiol. 2019;12(12):e007731.
10. Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus
Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction:
The CAMERA-MRI Study. J Am Coll Cardiol. 2017;70(16):1949-1961.
11. Parkash R, Wells GA, Rouleau J, et al. Randomized Ablation-Based
Rhythm-Control Versus Rate-Control Trial in Patients with Heart Failure
and Atrial Fibrillation: Results from the RAFT-AF trial.Circulation. 2022.
12. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused
Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients
With Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. J Am Coll Cardiol.2019;74(1):104-132.
13. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the
diagnosis and management of atrial fibrillation developed in
collaboration with the European Association for Cardio-Thoracic Surgery
(EACTS). European heart journal. 2021;42(5):373-498.
14. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between
sinus rhythm, treatment, and survival in the Atrial Fibrillation
Follow-Up Investigation of Rhythm Management (AFFIRM) Study.Circulation. 2004;109(12):1509-1513.
15. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate
control for atrial fibrillation and heart failure. N Engl J Med.2008;358(25):2667-2677.
16. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in
patients with congestive heart failure and left ventricular dysfunction.
Danish Investigations of Arrhythmia and Mortality on Dofetilide Study
Group. N Engl J Med. 1999;341(12):857-865.
17. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for
atrial fibrillation in patients with heart failure. N Engl J Med.2008;359(17):1778-1785.
18. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs
Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac
Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized
Clinical Trial. JAMA. 2019;321(13):1261-1274.
19. MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency
ablation for persistent atrial fibrillation in patients with advanced
heart failure and severe left ventricular systolic dysfunction: a
randomised controlled trial. Heart. 2011;97(9):740-747.
20. Sohns C, Zintl K, Zhao Y, et al. Impact of Left Ventricular Function
and Heart Failure Symptoms on Outcomes Post Ablation of Atrial
Fibrillation in Heart Failure: CASTLE-AF Trial. Circ Arrhythm
Electrophysiol. 2020;13(10):e008461.
21. Lima FV, Kennedy KF, Sheikh W, et al. Thirty-day readmissions after
atrial fibrillation catheter ablation in patients with heart failure.Pacing and clinical electrophysiology : PACE. 2020;43(9):930-940.
22. Peigh G, Wasserlauf J, Kaplan RM, et al. Repeat pulmonary vein
isolation with or without FIRM-guided ablation for recurrent atrial
fibrillation with pulmonary vein reconnection. J Cardiovasc
Electrophysiol. 2020;31(5):1031-1037.
23. Chew DS, Loring Z, Anand J, et al. Economic Evaluation of Catheter
Ablation of Atrial Fibrillation in Patients with Heart Failure With
Reduced Ejection Fraction. Circulation Cardiovascular quality and
outcomes. 2020;13(12):e007094.
24. Briceno DF, Markman TM, Lupercio F, et al. Catheter ablation versus
conventional treatment of atrial fibrillation in patients with heart
failure with reduced ejection fraction: a systematic review and
meta-analysis of randomized controlled trials. J Interv Card
Electrophysiol. 2018;53(1):19-29.
Fig. 1: Process of study selection